Teva Pharmaceutical (TEVA) news
Recent news
Teva to pay Bioxcel up to addl $67.5M in contingent payments
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has agreed to pay up to an additional $67.5 million in contingent payments to Bioxcel, as part of an ongoing collaboration to advance a biosimilar candidate for oncology treatments. This financial commitment is tied to the achievement of…
AInvest Wire · 3d agoTeva to buy Bioxcel rights for upfront $57.5M
AInvest Wire · 3d agoTva announces proposed acquisition of a novel neuroscience product reinforcing disciplined business development approach under pivot to growth strategy
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has announced the proposed acquisition of Emalex Biosciences, a move that aligns with its ongoing "Pivot to Growth" strategy. The acquisition includes an upfront payment of $700 million, with potential additional milestone payments of up to…
AInvest Wire · 3d agoBioXcel Therapeutics - Deal with Teva includes $57.5 mln cash, up to $67.5 mln development milestones, $20 mln commercial milestones - SEC filing
AInvest Wire · 3d agoBioxcel Therapeutics - Teva to serve as stalking horse bidder in 363 auction process
AInvest Wire · 3d agoLight Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.